000136787 001__ 136787
000136787 005__ 20240229105059.0
000136787 0247_ $$2doi$$a10.1002/ijc.31384
000136787 0247_ $$2pmid$$apmid:29574909
000136787 0247_ $$2ISSN$$a0020-7136
000136787 0247_ $$2ISSN$$a1097-0215
000136787 0247_ $$2altmetric$$aaltmetric:34907088
000136787 037__ $$aDKFZ-2018-01225
000136787 041__ $$aeng
000136787 082__ $$a610
000136787 1001_ $$0P:(DE-He78)2b1939dd3b00e62eeea7798367576c30$$aQuintana Pacheco, Daniel Antonio$$b0$$eFirst author$$udkfz
000136787 245__ $$aIron status in relation to cancer risk and mortality: Findings from a population-based prospective study.
000136787 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000136787 3367_ $$2DRIVER$$aarticle
000136787 3367_ $$2DataCite$$aOutput Types/Journal article
000136787 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536306485_14253
000136787 3367_ $$2BibTeX$$aARTICLE
000136787 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136787 3367_ $$00$$2EndNote$$aJournal Article
000136787 520__ $$aWhile experimental evidence suggests potential carcinogenic effects of increased iron load, there is a lack of data on iron status and cancer risk from epidemiological studies. Here, we evaluated prediagnostic serum concentrations of ferritin, iron and transferrin as well as transferrin saturation (TSAT) in relation to cancer risk and mortality in a prospective study by multivariable Cox regression analyses. A case-cohort sample of the population-based EPIC-Heidelberg Study including a random subcohort (n = 2738) and incident cases of breast cancer (n = 627), prostate cancer (n = 554), lung cancer (n = 195), colorectal cancer (n = 256) and cancer death (n = 759) was used. Ferritin levels were inversely associated with breast cancer risk in the multivariable Cox regression model, with a hazard ratio (HR) of 0.67 [95% confidence interval: 0.49, 0.92] for women in the highest quartile compared to those in the lowest quartile. Neither ferritin nor the other markers of iron status were significantly associated with colorectal, prostate or lung cancer risk. An inverse association was observed between ferritin and total cancer mortality (HR: 0.70 [0.53, 0.92]). There were no significant overall associations between serum iron, transferrin or TSAT and cancer mortality. The present findings do not support the notion of increased iron load constituting a cancer risk factor in the general population. By contrast, our analyses revealed inverse associations between ferritin levels and breast cancer risk as well as cancer mortality.
000136787 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136787 588__ $$aDataset connected to CrossRef, PubMed,
000136787 7001_ $$0P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be$$aSookthai, Disorn$$b1$$udkfz
000136787 7001_ $$0P:(DE-He78)9a183bfc8348c1db81a0ecf1458d0708$$aGraf, Mirja$$b2$$udkfz
000136787 7001_ $$0P:(DE-He78)ceb74219d144ab5760a228e71440c5ca$$aSchübel, Ruth$$b3$$udkfz
000136787 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b4$$udkfz
000136787 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b5$$udkfz
000136787 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b6$$udkfz
000136787 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b7$$eLast author$$udkfz
000136787 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31384$$gVol. 143, no. 3, p. 561 - 569$$n3$$p561 - 569$$tInternational journal of cancer$$v143$$x0020-7136$$y2018
000136787 909CO $$ooai:inrepo02.dkfz.de:136787$$pVDB
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2b1939dd3b00e62eeea7798367576c30$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9a183bfc8348c1db81a0ecf1458d0708$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ceb74219d144ab5760a228e71440c5ca$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000136787 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000136787 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136787 9141_ $$y2018
000136787 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136787 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136787 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136787 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136787 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000136787 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136787 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136787 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136787 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136787 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136787 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136787 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000136787 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000136787 980__ $$ajournal
000136787 980__ $$aVDB
000136787 980__ $$aI:(DE-He78)C020-20160331
000136787 980__ $$aUNRESTRICTED